| Robert N. Weingarten |
Robert N. Weingarten is currently the Chairman & Secretary at Guardion Health Sciences, Inc., the Director at Olympus Gold Mines Ltd., the Director at Falcon Mines SA, and the Chief Financial Officer & Vice President at Lixte Biotechnology Holdings, Inc. He previously served as the Non-Executive Chairman at New Dawn Mining Corp., the Chief Financial Officer, Director & Vice President at RespireRx Pharmaceuticals, Inc., and held various director positions at Aries Ventures, Inc., Central African Gold Ltd., Staffing 360 Solutions, Inc., Falcon Gold Zimbabwe Ltd., Youbet.com, Inc., ARTISTdirect, Inc., Matchaah Holdings, Inc., ALJ Regional Holdings, Inc., Brighton Technologies Corp., and Totaligent, Inc. He obtained his undergraduate degree from the University of Washington in 1974 and his MBA from the University of Southern California in 1975. |
| Eric J. Forman |
Eric J. Forman is currently a Member at the New York State Bar Association and the Chief Operating Officer & Vice President at Lixte Biotechnology Holdings, Inc. He previously worked as Counsel & Senior Project Manager at Shore Group Associates LLC. Mr. Forman completed his undergraduate degree at Loyola Marymount University and his graduate degree at Benjamin N. Cardozo School of Law. |
| James S. Miser |
James S. Miser is currently the Chief Medical Officer at Lixte Biotechnology Holdings, Inc. He previously held positions as Director-Department of Pediatric Hematology at City of Hope National Medical Center, Chief Medical Information Officer at Bumrungrad Hospital Public Co., Ltd., Professor at Taipei Medical University, and Chief Medical Officer at City of Hope National Cancer Institute. |
| Bastiaan van der Baan |
Bastiaan van der Baan is the founder of thromboDx BV, which was founded in 2011. He is currently the Chairman, President & Chief Executive Officer at Lixte Biotechnology Holdings, Inc. since 2022, an Independent Director at Tethis SpA since 2021, and a Venture Partner at Xgen Venture Sgr SpA since 2023. Mr. van der Baan previously worked as a Sales Manager at Unilever Plc, Chief Clinical & Business Development Officer at Agendia NV, and Chief Clinical & Business Development Officer at Agendia, Inc. from 2012 to 2023. He obtained a graduate degree from Wageningen University in 1996. |
| Stephen J. Forman |
Stephen J. Forman is currently the Chairman-Hematology at City of Hope Comprehensive Cancer Center since 1987. He is also an Independent Director at Lixte Biotechnology Holdings, Inc. since 2016. Additionally, he is a Member of the New York State Bar Association. Dr. Forman completed his undergraduate degree at Loyola Marymount University and his graduate degree at Benjamin N. Cardozo School of Law. |
| Yun Yen |
Yun Yen is currently the CEO, CFO, Secretary, and Director at Tanvex BioPharma USA, Inc. He is also the Chairman of The Chinese Oncology Society, Sino American Cancer Foundation, and Calgent Biotechnology Co. Ltd. Additionally, he is an Independent Director at Lixte Biotechnology Holdings, Inc. and a Director at Tanvex Biologics Corp. Dr. Yen's former positions include Chairman of OBI Pharma, Inc., Chairman of Tanvex BioPharma, Inc., and Associate Director of Translational Research at City of Hope Comprehensive Cancer Center. He was also a Professor at California Institute of Technology and President-Emeritus & Professor at Taipei Medical University. Dr. Yen holds a doctorate from Thomas Jefferson University and The College of William & Mary, and a graduate degree from National Taiwan University and a doctorate from Taipei Medical University. |
| René Bernards |
René Bernards is the founder of Agendia NV, founded in 2003, where he holds the title of Chief Scientific Officer. He is also the founder of Agendia, Inc., founded in 2003, where he holds the title of Chief Scientific Officer. Currently, Dr. Bernards is the Director at the American Association for Cancer Research since 2018. He is also an Independent Director at Lixte Biotechnology Holdings, Inc. since 2022. Additionally, he holds the position of Professor-Molecular Carcinogenesis at the University of Utrecht, is a Member of The Royal Netherlands Academy of Arts & Sciences, and serves as the Head-Molecular Carcinogenesis Division at Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh. |
| Regina Brown |
Regina Brown is associated with Lixte Biotechnology Holdings, Inc. as an Independent Director since 2021. She is also a Member of The American Institute of Certified Public Accountants and California Society of Certified Public Accountants. |
